Ariad Pharmaceuticals, Inc. (ARIA) Announces The Commercial Availability Of Iclusig (Ponatinib) For Patients With Refractory Philadelphia-Positive Leukemias In The U.S.
1/17/2014 8:18:40 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the commercial availability of Iclusig® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.
Help employers find you! Check out all the jobs and post your resume.